IBI363: clinical trials recruiting now
4
Recruiting trials
6
Conditions studied
6
US states with sites
2
Countries
Phase breakdown
Phase 2 4
Conditions being studied
| Condition | Trials |
|---|---|
| Melanoma · IBI363 for Melanoma | 3 |
| Lung cancer | 2 |
| Colorectal Cancer | 1 |
| Non-small Cell Lung Cancer | 1 |
| Renal Cell Cancer | 1 |
| Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer | 1 |
Recruiting trials involving IBI363
- A Study of IBI363 in Subjects With Advanced Melanoma
- A Study of IBI363 in Subjects with Advanced Solid Malignancies
- A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
- IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
Common questions
How many recruiting trials involve IBI363?
4 recruiting trials across 6 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.